A recent update from health authorities has informed users of certain hormonal contraceptives that there is a very small increased risk of developing a meningioma, which is a benign (non-cancerous) tumor that forms in the membranes surrounding the brain. This risk applies specifically to users of contraceptives containing desogestrel or etonogestrel, such as the implant Nexplanon or the pills Optimizette and Cerazette. Starting in September 2026, affected individuals will receive a personalized letter outlining this risk, which is extremely rare. Scientific data remains reassuring: a 2024 study showed that for every 67,000 women using these contraceptives, there is one additional case of meningioma. This is much lower than the risks associated with older hormonal treatments, such as Androcur, where the risk was significantly higher after long-term use. The increased risk is only slight and disappears completely after stopping the contraceptive. The duration of use plays a role: the risk becomes noticeable after at least one year of use and doubles beyond seven years. Women over 45 are advised to be somewhat more cautious, as the risk may appear earlier for them. This is also the case for people who have previously taken other progestogens known to increase the risk of meningioma, such as Lutényl or Colprone. However, the most important point is that this increased risk is completely reversible. After stopping the contraceptive for a year, the risk is no longer observed. Receiving a letter from health authorities can naturally cause concern, and the immediate reaction might be to stop using the contraceptive. However, the drug agency strongly advises against doing so without consulting a healthcare provider. Stopping abruptly could increase the risk of an unwanted pregnancy. There is no need to schedule an urgent medical appointment, and the recommended approach is to continue using the contraceptive as usual and discuss the matter calmly during the next routine check-up. Healthcare professionals have also received personalized letters with the same information, so they are well informed about the situation. While vigilance is important, the symptoms to monitor are generally common and not necessarily linked to meningioma. Persistent headaches, vision problems, muscle weakness, or loss of hearing or smell should be reported to a healthcare professional. Issues with balance, language, memory, or the appearance of epileptic seizures also justify a medical consultation. However, imaging tests are only prescribed if necessary. Contraception is not a lifelong commitment, and it is important to review your method annually with a healthcare provider, considering your lifestyle and medical history. This letter, while concerning, presents an opportunity to review your gynecological care without unnecessary alarm.